C5851
CGP 35348 hydrate
≥97% (NMR), solid
Synonym(s):
(3-Aminopropyl)(diethoxymethyl)phosphinic acid hydrate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
| Size/SKU | Availability | Price |
|---|---|---|
5 mg | Please contact Customer Service for Availability | CZK 5,060.00 CZK 4,301.00 |
25 mg | Please contact Customer Service for Availability | CZK 17,400.00 |
About This Item
Empirical Formula (Hill Notation):
C8H20NO4P · xH2O
CAS Number:
Molecular Weight:
225.22 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥97% (NMR)
Form:
solid
Storage condition:
desiccated
CZK 4,301.00
List PriceCZK 5,060.00Save 15%Please contact Customer Service for Availability
Quality Segment
assay
≥97% (NMR)
form
solid
storage condition
desiccated
color
white
solubility
H2O: >20 mg/mL
originator
Novartis
storage temp.
−20°C
SMILES string
O.CCOC(OCC)P(O)(=O)CCCN
InChI
1S/C8H20NO4P.H2O/c1-3-12-8(13-4-2)14(10,11)7-5-6-9;/h8H,3-7,9H2,1-2H3,(H,10,11);1H2
InChI key
SRBHGEXMDCJOMS-UHFFFAOYSA-N
Application
CGP 35348 hydrate has been used as a γ-aminobutyric acid-B (GABAB) receptor inhibitor:
- to study its effects on intrinsic optical signal (IOS) in rat hippocampus[1]
- alone or in combination with sodium salicylate to study its effects on auditory responses in the rat′s dorsal cortex of rat[2]
- to study its effects on hepatocellular carcinoma cells (HCC)[3]
Biochem/physiol Actions
CGP 35348 is a γ-aminobutyric acid-B (GABAB) receptor antagonist. It has a higher affinity towards post-versus presynaptic receptors that can penetrate the blood-brain barrier.[4]
Features and Benefits
This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the GABAB Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Disclaimer
Product is hygroscopic
1 of 1
This Item | |||
|---|---|---|---|
| form solid | form powder | form powder | form solid |
| assay ≥97% (NMR) | assay ≥97% (NMR) | assay ≥98% (HPLC) | assay ≥97% (HPLC) |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
| storage temp. −20°C | storage temp. room temp | storage temp. 2-8°C | storage temp. room temp |
| storage condition desiccated | storage condition desiccated | storage condition desiccated | storage condition - |
| solubility H2O: >20 mg/mL | solubility H2O: 10 mg/mL (clear solution, warmed) | solubility H2O: 1 mg/mL, clear (warmed) | solubility H2O: ≥5 mg/mL |
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.